MAIA Bio - MAIA Company Short-Term Debt

MAIA Biotechnology, Inc. (MAIA) - corporate logo

The short-term debt trend of MAIA Biotechnology complements the diversification strategy of its solid tumor treatment programs to minimize patent risks. The 0.00 metric determines the liquidity parameter status, which is critical given that success depends on the funding of telomere therapy trials. The competitive advantage is based on the THIO platform, although commercial protection will only emerge upon the completion of phase III trials.

MAIA: MAIABiotech.com Short-Term Debt 04/28/2023 - 10/28/2026

MAIA (MAIA Bio): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart MAIA Biotechnology, Inc.|MAIA - Average Forecast Price
- market capitalization data:
Market Value MAIA Biotechnology, Inc.|MAIA - Total Company Value
- book capitalization data:
Net Assets per Single Share MAIA Biotechnology|MAIA - Total Stockholders' Equity|Market Capitalization to Book Value Ratio MAIABiotech.com|MAIA - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Equity Ratio MAIA Biotechnology|MAIA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio MAIA Biotechnology|MAIA - Aggregate Debt Obligations|Debts to Book Capitalization MAIA Biotechnology, Inc.|MAIA - Long-Term Debt Volume|Company Short-Term Debt MAIA Biotechnology
Analysis of all company metrics:MAIA Biotechnology, Inc. MAIA
Finished products of MAIABiotech.com

Short-term debt measures the total liabilities with a maturity of up to one year, determining a business's ability to service its accounts payable without the emergency raising of capital. By analyzing the company's current liabilities, an investor assesses the liquidity risk of MAIA Biotechnology, whose scientific reputation in targeted immunotherapy requires stable funding for research into destroying tumors by targeting telomeres.

Competitor analysis for MAIA Biotechnology

IBRX (ImmunityBio) - Company Short-Term Debt|IMCR: Short-Term Debt|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt ZYME (Zymeworks Inc.)|Short-Term Debt tangotx.com|IOVA: Company Short-Term Debts|Short-Term Indebtedness Immatics NV IMTX|XNCR: Company Current Liabilities|CMPX - Short-Term Debt|Company Current Liabilities Replimune Group, Inc. (REPL)|LYEL - Company Short-Term Loans and Borrowings|Innate Pharma - Company Short-Term Debts|PYXS (Pyxis Oncology) - Short-Term Debt Volume|Company Short-Term Debt CGEN|Company Current Liabilities IOBT|Company Short-Term Debt STRO (Sutro Biopharma, Inc.)|Company Current Liabilities minktherapeutics.com INKT|Company Current Liabilities HOWL (Werewolf Therapeutics, Inc.)|Immix Biopharma Inc. - Company Short-Term Debts|ALX Oncology (ALXO) - Company Short-Term Debt|CUE: Company Short-Term Indebtedness|Company Short-Term Debt PDSB|Short-Term Debt Sonnet BioTherapeutics Holdings|Liminatus Pharma LLC - Company Current Liabilities|Short-Term Indebtedness Lava Tx (LVTX)|Company Current Liabilities NextCure Corp|Amount of Current Liabilities leaptx.com (LPTX)|Company Short-Term Debts Intensity Therapeutics, Inc.|Company Short-Term Loans and Borrowings Sensei Biotherapeutics Inc SNSE|TOVX (Theriva Biologics) - Company Short-Term Debts|GRTS: Short-Term Debt|Company Short-Term Debt Kineta Bio KA|NexImmune Corporation (NEXI) - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts VCNX|HARP - Company Short-Term Debt